Thera-SAbDab

LORVOTUZUMAB

>   Structural Summary
TherapeuticLorvotuzumab
TargetNCAM1
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS
Light ChainDVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedImmunoGen
Conditions Approvedna
Conditions ActiveHaematological malignancies
Conditions DiscontinuedMultiple myeloma, Solid tumours, Small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]